REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of TAKEDA
19/11/2018 15:05
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181116:nRSP8071Ha
RNS Number : 8071H
Morgan Stanley
19 November 2018
AMENDMENT Section (2a) & (3a)
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR
WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form Takeda Pharmaceutical Company Limited
relates:
Use a separate form for each offeror/offeree
(c) Name of the party to the offer with which exempt principal trader is Shire plc
connected:
(d) Date position held/dealing undertaken: 15 NOVEMBER 2018
For an opening position disclosure, state the latest practicable date
prior to the disclosure
(e) In addition to the company in 1(b) above, is the exempt principal trader YES - Shire plc
making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE EXEMPT PRINCIPAL
TRADER
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(b), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing
(if any)
Class of relevant security: Ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 11,613,923 1.48 29,881,613 3.81
(2) Cash-settled derivatives: 29,472,585 3.76 10,897,171 1.39
(3) Stock-settled derivatives (including options) and agreements to 185,000 0.02 185,000 0.02
purchase/sell:
41,271,508 5.26 40,963,784 5.22
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors'
and other employee options)
Class of relevant security in relation to which subscription right exists: N/A
Details, including nature of the rights concerned and relevant percentages: N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchases/sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary PURCHASES 808,276 4,514.8050 JPY 4,388.0000 JPY
Ordinary SALES 971,352 4,514.8050 JPY 4,388.0000 JPY
(b) Cash-settled derivative transactions
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short
position
Ordinary CFD LONG 500 4422.4000 JPY
Ordinary CFD LONG 7400 4440.0000 JPY
Ordinary CFD SHORT 100 4412.0000 JPY
Ordinary CFD LONG 500 4409.0000 JPY
Ordinary CFD SHORT 200 4402.5000 JPY
Ordinary CFD SHORT 5000 4405.5200 JPY
Ordinary CFD LONG 12300 4403.4552 JPY
Ordinary CFD LONG 200 4392.5000 JPY
Ordinary CFD SHORT 200 4440.0000 JPY
Ordinary CFD SHORT 400 4404.0000 JPY
Ordinary CFD LONG 2200 4395.9822 JPY
Ordinary CFD LONG 1000 4440.0000 JPY
Ordinary CFD SHORT 1000 4402.3000 JPY
Ordinary CFD SHORT 2500 4400.9200 JPY
Ordinary CFD LONG 11100 4407.0000 JPY
Ordinary CFD LONG 6100 4401.7765 JPY
Ordinary CFD LONG 1300 4398.1300 JPY
Ordinary CFD LONG 200 4395.0000 JPY
Ordinary CFD SHORT 1500 4402.5333 JPY
Ordinary CFD LONG 22300 4438.4034 JPY
Ordinary CFD LONG 1000 4438.4034 JPY
Ordinary CFD LONG 1100 4401.4545 JPY
Ordinary CFD LONG 20300 4410.4458 JPY
Ordinary CFD SHORT 38100 4402.1154 JPY
Ordinary CFD SHORT 400 4407.7500 JPY
Ordinary CFD SHORT 300 4388.0000 JPY
Ordinary CFD SHORT 14200 4500.0000 JPY
Ordinary CFD LONG 14200 4500.0000 JPY
Ordinary CFD LONG 2600 4500.0000 JPY
Ordinary CFD SHORT 5200 4447.3461 JPY
Ordinary CFD SHORT 500 4434.2000 JPY
Ordinary CFD LONG 7300 4432.3174 JPY
Ordinary CFD LONG 2500 4404.2957 JPY
Ordinary CFD SHORT 12700 4412.9892 JPY
Ordinary CFD LONG 147076 4402.2999 JPY
Ordinary CFD SHORT 12500 4396.9440 JPY
Ordinary CFD SHORT 2000 4514.8050 JPY
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
N/A N/A N/A N/A N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
N/A N/A N/A N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the exempt
principal trader making the disclosure and any party to the offer or any
person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the exempt principal trader making the disclosure and any other person
relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 19 NOVEMBER 2018
Contact name: Craig Horsley
Telephone number: +44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service and must also be emailed to the Takeover Panel at
monitoring@disclosure.org.uk (mailto:monitoring@disclosure.org.uk) . The
Panel's Market Surveillance Unit is available for consultation in relation to
the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR
SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
4. KEY INFORMATION
Identity of person whose open positions are being disclosed: Morgan Stanley MUFG Securities Co., Ltd.
Name of offeror/offeree in relation to whose relevant securities the Takeda Pharmaceutical Company Limited
disclosure relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security Product Description e.g call option Written or Purchased Number of Securities to which option or derivative relates Exercise Price Per Unit (USD) Type Expiry Date
Ordinary PUT PURCHASED 125,000 4507.0000 JPY European 13/12/2019
Ordinary CALL PURCHASED 125,000 4507.0000 JPY European 13/12/2019
Ordinary PUT PURCHASED 60,000 4596.0000 JPY European 14/06/2019
Ordinary CALL PURCHASED 60,000 4596.0000 JPY European 14/06/2019
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position
can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions)
with regard to contracts for differences ("CFDs") or spread bets.
The currency of all prices and other monetary amounts should be stated.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement